Follow the Pundits

Tag: hub-health

The insider action happened at Kenvue — but the longer-term value story may actually belong to Kimberly-Clark. The two tickers KMB and KVUE merge or emerge together.

Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?

A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.

Read entire article

Tags: buy or sell kmb, Consumer Healthcare Stocks, consumer staples, director buying, Director Purchases, Dividend Stocks, Follow the Pundits, FUNanc1al, FUNanc1al Edge, Funanc1al Humor, hub-health, hub-insiders, hub-value, Insider Buying, Insider Purchases, Jeff Smith, Kenvue, Kimberly-Clark, KMB, KVUE, Mergers & Acquisitions, risks buying kmb, Starboard Value, Value Stocks, why buy kmb
Whimsical illustration of targeted protein degradation: glowing STAT6 protein being tagged with ubiquitin while a proteasome vacuum removes it; Baker Bros figures analyzing the process with excitement; biotech humor meets scientific innovation.

Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?

Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?

Read entire article

Tags: Asthma therapeutics, Atopic Dermatitis, Baker Bros Advisors, Biotech Expertise, Biotech Investing, Biotech Stocks, Buy or sell KYMR, Clinical Trials, Fast Track FDA, featured-hedge-funds, Funanc1al Edge, FUNanc1al Humor, funanc1al investing, FUNstock Index, Hedge Fund Moves, hub-epiphany, hub-health, hub-hedge, hub-insiders, hub-techbio, Immunology, Insider Buying, Kymera stock, Kymera Therapeutics, KYMR, Risks Investing in KYMR, STAT6 degrader, Targeted Protein Degradation, why buy KYMR